首页 >
法规速递
-
Document: Timetable: Post-authorisation measure (PAM) assessed by CHMP-2025/9/24
2025-09-25查看详情 > -
Page: PRIME: priority medicines-2025/10/31
2025-11-03查看详情 > -
Document: Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease-2025/12/1
2025-12-02查看详情 > -
Page: Emergency Task Force (ETF)-2026/1/5
2026-01-06查看详情 > -
Document: New product information wording: extracts from PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC-2026/2/9
2026-02-10查看详情 > -
Pyrogen and Endotoxins Testing: Questions and Answers-2026/3/18
2026-03-19查看详情 > -
Document: Opinion of the CVMP on the establishment of maximum residue limits: Lidocaine (EMEA/V/MRL/003649/MODF/0004)-2026/4/21
2026-04-22查看详情 > -
Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment(Draft)-2023/02/24
2023-02-24查看详情 > -
国家药监局关于适用《Q9（R1）：质量风险管理》国际人用药品注册技术协调会指导原则的公告 （2023年第114号）-2023/9/5
2023-09-06查看详情 > -
Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act-2025/1/6
2025-01-07查看详情 >
